PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 4 :
C12Q 1/68, 1/70
C07C 107/00, G01N 33/566

A1

(11) International Publication Number: WO 89/09833

(43) International Publication Date: 19 October 1989 (19.10.89)

(21) International Application Number: PCT/US89/01361

(22) International Filing Date: 31 March 1989 (31.03.89)

(30) Priority data:
175,970 31 March 1988 (31.03.88) US

(71)(72) Applicant and Inventor: MILLS, Randell, L. [US/US]; R.D. 2, Cochranville, PA 19330 (US).

(74) Agents: MATZUK, Stephen, G. et al.; Weingarten, Schurgin, Gagnebin & Hayes, Ten Post Office Square, Boston, MA 02109 (US).

(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), HU, IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), SU.

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS

(57) Abstract

A broad class of pharmaceutical agents which react directly with electron carriers or with reactive species produced by electron transport to release a pharmacologically active molecule to effect a therapeutic functional change in the organism by a receptor or nonreceptor mediated action.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	**FR**	France	**ML**	Mali
AU	Australia	**GA**	Gabon	**MR**	Mauritania
BB	Barbados	**GB**	United Kingdom	**MW**	Malawi
BE	Belgium	**HU**	Hungary	**NL**	Netherlands
BG	Bulgaria	**IT**	Italy	**NO**	Norway
BJ	Benin	**JP**	Japan	**RO**	Romania
BR	Brazil	**KP**	Democratic People's Republic of Korea	**SD**	Sudan
CF	Central African Republic			**SE**	Sweden
CG	Congo	**KR**	Republic of Korea	**SN**	Senegal
CH	Switzerland	**LI**	Liechtenstein	**SU**	Soviet Union
CM	Cameroon	**LK**	Sri Lanka	**TD**	Chad
DE	Germany, Federal Republic of	**LU**	Luxembourg	**TG**	Togo
DK	Denmark	**MC**	Monaco	**US**	United States of America
FI	Finland	**MG**	Madagascar		

LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS

FIELD OF THE INVENTION

The present invention relates to therapeutic pharmaceutical agents which are activated intracellularly by reaction with cellular electron carriers or free radicals to cause release of a free and active drug molecule.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation in part of my co-pending U.S. Patent Application Serial No. 948,326, entitled LUMINIDE CLASS OF PHARMACEUTICALS, filed December 31, 1986.

BACKGROUND OF THE INVENTION

The effects of the preponderance of drugs result from their interaction with functional macromolecular components of the organism. Such interaction alters the function of the pertinent cellular component and thereby initiates the series of biochemical and physiological changes that are characteristic of the response to the drug. The term receptor denotes the component of the organism with which the chemical agent interacts. There are fundamental corollaries to the statement that the receptor for a drug can be any functional macromolecular component of the organism. One is that a drug is potentially capable of altering the rate at which any bodily function proceeds; a second is that, by virtue of interactions with specific receptors, drugs do not create effects

but merely modulate the rates of ongoing functions. A simple pharmacological dictum thus states that a drug cannot impart a new function to a cell. Functional changes due to a drug result from either enhancement or inhibition of the unperturbed rate. Furthermore, a drug that has no direct action can cause a functional change by competition for a binding site with another, active regulatory ligand of the receptor. Drugs are termed agonists when they cause effects as a result of direct alteration of the fundamental properties of the receptor with which they interact. Compounds that are themselves devoid of intrinsic pharmacological activity but cause effects by inhibition of the action of a specific agonist (eg. by competition for agonist binding sites) are designated as antagonists.

At least from a numerical standpoint, the proteins of the cell form the most important class of drug receptors. Obvious examples are the enzymes of crucial metabolic or regulatory pathways (eg., tyrosine hydroxylase; 3-hydroxy-3-methylglutaryl - CoA reductase), but of equal interest are proteins involved in transport processes (eg. Ca^{2+} - ATPase; Na^{+} - K^{+} - ATPase) or those that are protein kinases which activate other proteins as a consequence of their binding a secondary messenger such as cAMP. Specific binding properties of other cellular constituents can be exploited. Thus, nucleic acids are important drug receptors, particularly for chemotherapeutic approaches to the control of malignancy, and plant lectins shown remarkable specificity for recognition of specific carbohydrate residues in polysaccharides and glycoproteins. Small ions such as Ca^{2+} which can function as a regulatory ion or Fe^{2+} which can

serve as an essential enazmatic cofactor can be exploited as drug receptors. And, drugs can also produce a functional change by a nonreceptor-mediated action. Certain drugs that are structural analogues of normal biological constituents may be incorporated into cellular components and thereby alter their function. This has been termed a "counterfeit incorporation mechanism" and has been implemented with analogues of purines and pyrimidines that can be incorporated into nucleir acids and that have utility in cancer chemotherapy and that have antiviral activity. Also, specific constituents of pathogens can be exploited as receptors. For example, the electron carriers of bacterial can serve as receptors as described in my previous U.S. Patent Application Serial No. 948,326, and the replicative enzymes of viruses can be serve as receptors as described below for the virus HIV. Many compounds are known which have receptor or nonreceptor mediated in vitro activity as appears in Handbook of Enzyme Inhibitors, Mahendra Kumor Jain, 1982, Wiley Interscience, New York, hereby incorporated by reference. However, only a small percentage produce the desired functional change in vivo or have a high therapeutic ratio because they are toxic in their free form; they are rapidly inactivated or excreted; or, they cannot obtain access to their target receptor or site of action because they are impermeant to cells or biological barriers such as the blood brain barrier due to unfavorable energetics due, for example, to the possession of polar or charge groups; or, they are toxic as a consequence of being nonselective with regards to their access to and action with receptors in one biological environment or compartment relative to another. In these cases, compounds which

demonstrate in vitro efficacy are ineffective therapeutics.

SUMMARY OF THE INVENTION

A broad class of pharmaceutical agents is disclosed herein as the Luminide class of pharmaceuicals. Luminide agents are three part or four part molecules where each part is a functionality with a defined purpose. Exemplary Luminides are A-B-C , D-A-B-C, A-D-B-C, and A-B-C
\
D
where A represents a functionality which is activatable by the environment and capable of transferring energy from its own excited state to the B functionality which is an energy acceptor. Upon receiving energy from A, B achieves an excited state which relaxes through the heterolytic cleavage of the covalent bond of B with C where C is a drug moiety which is released into the intracellular compartment where activation of A occured. Released C can act locally or at a distant site. D serves as an electron transfer functionality which gains (loses) electrons from (to) the environment and donates (accepts) electrons to (from) A to activate it so that the energy of excited A is transferred to B with release of C as occurs for the three functionality case.

In both cases, free C is a drug molecule. The released drug molecule effects a therapeutic functional change by a mechanism which comprises receptor mediated mechanisms including reversible or irreversible competitve agonism or antagonism including a suicide substrate or transition state analogue mechanism or a noncompetitive or

uncompetitve agonism or antagonism or the action is by a nonreceptor mediated mechanism including a "counterfeit incorporation mechanism".

The chemical and physical properties of the Luminide agents such as permeance and reactivity to different oxidoreductase enzymes, electron carriers, or different free radicals including those of oxygen are exploited to control the environment into which C is released. Permeance of the Luminide agent to the blood brain barrier or cell membranes, or affinity of the Luminide agent to plasma proteins which results in a decreased excretion rate relative to free C, or lack of reactivity of extracellular enzymes with the Luminide agent relative to free C are exemplary mechanism where by Luminides provide for the release of active free C in the proper biological compartment or in the presence of the target receptor so that the desired therapeutic change is achieved. Thus, Luminides serve as therapeutic drugs. And, the present invention, Luminides, a broad class of pharmaceutical agents comprises antilipidemic drugs, anticholesterol drugs, contraceptive agents, anticoagulants, anti-inflamatory agents, immuno-suppressive drugs, antiarrhythmic agents, antineoplastic drugs, antihypertensive drugs, epinephrine blocking agents, cardiac inotropic drugs, antidepressant drugs, diuretics, antifungal agents, antibacterial drugs, anxiolytic agents, sedatives, muscle relaxants, anticonvulsants, agents for the treatment of ulcer disease, agents for the treatment of asthma and hypersensitivity reactions, antithroboembolic agents, agents for the treatment of muscular dystrophy, agents to effect a therapeutic abortion, agents for the treatment of anemia, agents to improve allograft survival, agents for the

treatment of disorders of purine metabolism, agents for the treatment of ischemic heart disease, agents for the treatment of opiate withdrawal, agents which activate the effects of secondary messenger inositol triphosphate, agents to block spinal reflexes, and antiviral agents including a drug for the treatment of AIDS.

DETAILED DESCRIPTION OF THE INVENTION

Electron transferring and transporting elements are ubiquitous and are necessary for life. All eukaryotic and prokaryotic organisms depend on electron transferring and transporting elements which include metal containing hemes and nonmetal containing molecules such as flavins to convert the energy stored in the chemical bonds of foodstuffs into a form utilizable for the maintenance of the highly negative entropic state of life. The chemical energy conversion process generally involves a coupled series of electron carriers which is called an electron transport chain.

Free radicals of oxygen are produced during aerobic respiration in mitochondria as electrons are carried by electron carriers of the electron transport chain to the ultimate electron acceptor, oxygen, and superoxide and peroxide, partial reduction products of oxygen, are continuously produced during cytosolic hydroxylation and oxygenation reactions as well as during other reactions which involve enzymatic reduction of oxygen. The cytosol as well as mitochondria of aerobic cells contain high concentrations of the enzyme superoxide dismutase which converts superoxide into hydrogen peroxide and molecular oxygen. Oxygen

radicals which include hydrogen peroxide and superoxide are found in greater concentration in the mitochondria relative to the cytosol because reduction of oxygen occurs to a greater extent in the former compartment; however, appreciable concentration are found in both compartments.

Luminides are agents which are permeant to the desired biological compartment which undergo an oxidation reduction reaction with the target cell's electron carriers or react with free radicals produced as a consequence of electron transport and release a drug moiety into the desired compartment in active form to effect a greater therapeutic effect or therapeutic ratio relative to the free C agent as a consequence of altered pharmacokinetics or pharmacodynamics such as a desirable kinetics of release, a resistance to inactivation or excretion, greater solubility, enhanced absorption, a diminished toxicity, or greater access to the cellular or biological compartment which is the site of action of C.

Luminide agents are three or four part molecules where each part is a functionality with a defined purpose. Exemplary Luminides are A-B-C, D-A-B-C, A-D-B-C and A-B-C
|
D

where A represents a functionality which undergoes an oxidation reduction reaction where electrons are transferred directly between A and the target cell's electron carriers or the electrons are transferred indirectly through an electron transfer functionality, D, which is described in more detail below. Alternatively, A represents a functionality which undergoes a reaction with free radicals of oxygen which are produced as a consequence of

electron transport. An excited state is produced in A as a consequence of its participation in one of these reactions. Then A undergoes intramolecular energy transfer from its own excited state to the B functionality which is an energy acceptor. Upon receiving energy from A, B achieves an excited state which relaxes through heterolytic cleavage of the covalent bond of B with C where C is a drug moiety which is released into the environment. D serves as an electron transfer functionality which gains (loses) electrons from (to) the environment and donates (accepts) electrons to (from) A to activate it so that the energy of excited A is transferred to B with release of C as occurs for the three functionality case. In both cases, free C is a drug molecule. The released drug molecule effects a therapeutic functional change by a mechanism which comprises receptor mediated mechanisms including reversible and irrereversible competitive agonism or antagonism including a molecle known as a suicide substrate or a transition state analogue mechanism or a noncompetitive or uncompetitive agonism or antagonism or the action is by a nonreceptor mediated mechanism including a "counterfeit incorporation mechanism".

The energy donating funtionality, A, is a molecule which reacts as previously described to form an excited state of high enough energy so that this subsequently transferred energy is of sufficient magnitude to break the covalent bond between the drug functionality, C, and the energy acceptor functionality, B. Chemiluminescent molecules can form highly excited states of the proper magnitude of energy, can undergo oxidation reduction reactions or react with free radicals, and possess a metastable

excited state from which intramolecular energy transfer can occur; thus, they can serve as the A functionality. In general, chemiluminescent molecules relevant to this invention can be placed into three categories: 1) molecules undergoing reaction involving peroxides and oxygen free radicals; 2) molecules undergoing reaction involving oxidation or reduction and 3) molecules undergoing both reaction with peroxides and oxygen free radicals followed by an oxidation or reduction reaction. Molecules of the first category include Lophine and its derivatives, acridinium esters and acridans, tetraphenylpyrrole, phthalhydrazides, acyloins, biacridinium salts, vinylcarbonyls, vinylnitriles, tetrakis (dimethylamino) ethylene, acylperoxides, indoles, tetracarbazoles and active oxalates. Molecules belonging to the second category include ruthenium chelates 2, 6-diaminopyrene, or cation radicals and molecules which follow a Chemically Initiated Electron Exchange Luminescence mechanism such as certain dioxetans and dioxetanones. Dioxene derivatives belong to the third category. They form a dioxetan by reation with superoxide and then produce efficient chemiluminescence by a CIEEL mechanism.

As an example from the first category, the chemiluminescent compound, luminol, has a chemiluminescent maximum in the region 390-400 nm in an aqueous solution. Chemiluminescence is produced by the reaction of luminol with oxygen free radicals where a large fraction of the product molecules are formed in their excited state. The nature of the excited state is electronic, and it has a mean lifetime of the order of 10^{-8} seconds which is typically ten thousand times the period of a

molecular vibration. Emission involves a quantum mechanically allowed singlet to singlet transition with energy of the order of 75 Kcal/mole. The quantum yield for forming the excited electronic state is 0.5. Because luminol undergoes a chemiluminescent reaction with oxygen radicals, this compound has been used as a molecular probe for these radicals by linkage to a molecule which directs the probe to a cellular compartment. For example, when luminol is attached to carnitine, the probe is transported into mitochondria and the intensity of chemiluminescence produced is proportional to the magnitude of electron transport activity which produces oxygen radicals. The chemiluminescent molecule, lucigenin, is also used as a probe for oxygen free radicals.

As for members of the second category, chemiluminescent molecules which undergo a redox reaction to produce an excited state react directly with electron carriers of the cell or undergo a redox reaction with the electron transfer functionality D.

As for the third category, a D functionality is optional. A chemiluminescent molecule of this category reacts with oxygen free radicals and forms an excited state, and chemiluminescence is produced but properties such as quantum yield or the relative ratio of singlet to triplet excited state can be altered by the transfer of electrons involving for example a D functionality. See Table 1 below for chemiluminescent molecules.

Table 1 Representative Chemiluminescent Molecules

Name	Structure
2, 6-diaminopyrene	
Aminophthalhydrazide	
Dioxene	
Imidazole derivaties	
Sulfonyloxamides	

Indole derivatives



Tetrakis(dialkylamino)ethylene



2,5,7,8-tetraoxabicyclo-[4.2.0.] octane



Dioxetan



Lucigenin



Lophine



Acridinium esters



Active oxalate



Tris-2,2'-bipyridinedichlororuthenium (II)



Dioxetanone



Dipheyl peroxide



Exemplary energy acceptor molecules include those which demonstrate photochromic behavior with electromagnetic radiation and bleaching agents. If the A functionality is chemiluminescent, then the B functionality is such that the photodissociative drug release spectrum of B overlaps the chemiluminescence spectrum of A.

Triarylmethane dyes react with cyanide to form nitriles called leucocyanides which liberate cyanide ion with a quantum yield of approximately one when irradiated with UV light in the wavelength range of 250 to 320 nm.



The spectrum of the photorelease reaction of cyanide ion can be extended to longer wavelengths in the case of triarylmethane dyes by substitutions of a naphthylene for an aryl group and also by using cationic polymethine dyes. The latter form nitriles, which are thermally stable, by the reaction of the carbonium ion of the dye with cyanide. The formation of the nitrile causes the colored dye to be bleached as is the case with triarylmethane dyes, and cyanide is released as the dye becomes colored upon absorption of 320-415 nm. Reversible bleaching by an agent and coloration by light is photochromic behavior.

Cationic dyes demonstrate this behavior and include di and triarylmethane dyes, triarylmethane lactones and cyclic ether dyes, cationic indoles, pyronines, phthaleins, oxazines, thiazines, acridines, phenazines, and anthocyanidins, and cationic polymethine dyes and azo and diazopolymethines, styryls, cyanines, hemicyanines, dialkylaminopolyenes, and other related dyes. See Table 2 below for structures for salt isomerism-type photochromic dyes. These photochromic molecules form covalent bonds with a number of agents called bleaching agents because they convert the compounds from colored to colorless form during bond formation. Bleaching agents are diverse and include hydroxide, cyanide, azide, bisulfide, and sulfite compounds, thiocyanate, ferrocyanide, chromate, tetraborate, acetate, nitrite, carbonate, citrate, aluminate, tungstate, molybdate, methoxide, 2-methoxyethoxide, cinnamate, and p-methoxycinnamate salts, and thiols and amines.

TABLE II

Dye Name or Structure; CI Name and Number; Other Names		*Nominal Anion*[a,b]	*Notes Referring to Solvent*[b]	*Visible Spectrum*	
				λ_{max} (nm)	*Solvent*
Malachite Green	42000	CN, SO_3H, OH	*c cc*	622	Ethanol
				617	Water
Helvetia Green	42020	CN	*dd, ee*		
Basic Blue 1	42025	CN, SO_3H	*c, h, aa*	640	Ethanol
Brilliant Blue				628	Water
Setoglaucine					
Basic Green 1	42040	CN, SO_3H	*c, d, g, h,*	633	Ethanol
Brilliant Green			*m-o, u*	622	Water
Acid Blue 1	42045	CN	*dd, ee*	628	Ethanol
Xylene Blue VS				636	Water
Patent Blue V					
Alphazurine 2G					
Acid Blue 3	42051	CN	*s, dd, ee*	632	Water
Brilliant Blue V					
Patent Blue V					
Food Green 3	42053	CN	*dd, ee*		
FDC Green 3					
Acid Green 6	42075	CN, SO_3H	*dd, ee*	629	Ethanol
Light Green SF Bluish				628	Water
Acid Blue 7	42080	CN	*s, dd, ee*	628	Ethanol
Xylene Blue AS				633	Water
Patent Blue A					
Acid Green 3	42085	CN, SO_3H	*dd hh*	626	Ethanol

Acid Blue 9 Erioglaucine	42090	CN	*s, dd, ee*	626	Water
Acid Green 5 Light Green SF Yellowish	42095	CN, SO_3H	*dd, ee, hh*	634 634	Ethanol Water
Acid Green 9 Erioviridene B	42100	CN, SO_3H	*ff-hh*	640 635	Ethanol Water
Acid Blue 147 Xylene Cyanol FF	42135	CN	*dd, ee*		
Basic Red 9 Pararosaniline	42500	CN, SO_3H, OH	*c, d, g, h,* *n, o, u,* *ff ii*	550 543	Ethanol Water
Basic Violet 14 Fuchsin Magenta	42510	CN, SO_3H	*ff-hh*	545	Water
Basic Fuchsin	42510B	SO_3H	*hh*	539	Water
Basic Violet 2 New Fuchsin New Magenta	42520	CN, SO_3H	*ff-hh*	544	Water
Hoffman Violet Iodine Violet	42530	SO_3H		584	Water
Basic Violet 1 Methyl Violet	42535	CN, SO_3H	*c, e, g, k,* *u, jj, kk*	588 584	Ethanol Water
Basic Violet 13 Methyl Violet 6B	42536	SO_3H		585	Water
Basic Violet 3 Crystal Violet Gentian Violet	42555	CN, SO_3H, OH	*c, d, g, h,* *n-p, u,* *ff ii, kk oo*	595	Ethanol
Iodine Green	42556	SO_3H			

Dye Name or Structure; CI Name and Number; Other Names		*Nominal Anion*[a,b]	*Notes Referring Solvent*[b]	*Visible Spectrum*	
				λ_{max} (nm)	*Solvent*
Basic Blue 8	42563	CN	*aa*	594, 538	Water
Victoria Blue 4R					
Acid Blue 13	42571	CN	*s, dd, ee*	611	Water
Fast Acid Violet 10B					
Acid Blue 75	42576	SO_3H		626	Ethanol
Eriocyanine A				614	Water
Methyl Green	42585	CN	*c, j, dd*	640	Ethanol
				634	Water
Ethyl Green	42590	CN	*s, dd hh*		
Basic Violet 4	42600	CN, SO_3H	*s*	597, 546	Water
Ethyl Violet					
Acid Violet 49	42640	CN, SO_3H	*dd, ee*	608, 544	Water
Wool Violet 5BN					
Acid Blue 15	42645	SO_3H		554	Water
Brilliant Milling Blue B					
Acid Violet 17	42650	CN, SO_3H	*s, dd hh*	591, 548	Ethanol
Acid Violet 6B				592, 539	Water
Wool Violet 4BN					
Formyl Violet					
Acid Violet 5BS Conc.					
Acid Violet 19	42685	CN, SO_3H	*ff-hh,*	545	Water

Acid Fuchsin			*pp–rr*			287, 291, 305
Red Violet 5R	42690	SO_3H				281
Acid Blue 22	42755	CN, SO_3H	*dd, ee, hh*	590	Ethanol	281, 284, 286,
Aniline Blue				607	Water	292, 293
Soluble Blue						
Solvent Blue 3	42775	SO_3H	*hh*	595	Ethanol	284
				590	Methanol	
Acid Blue 93	42780	CN, SO_3H	*ff, hh*	606	Ethanol	284, 287
Methyl Blue				586	Water	
Aurin	43800	CN, OH	*ss, tt*			306, 307
Mordant Blue 3	43820	SO_3H		588	aq. OH^-	281
Eriochrome Cyanine R						
Acid Green 16	44025	CN	*ee, tt*	638	Ethanol	303, 307, 310
Naphthalene Green V				639	Water	
Pontacyl Green NV Extra						
Basic Blue 11	44040	CN, SO_3H	*e, uu*	615, 558	Water	280, 281
Victoria Blue R						
Basic Blue 15	44085	SO_3H		628, 568	Water	281
Night Blue						
Acid Green 50	44090	CN	*ee, tt*	628	Ethanol	303, 311
Wool Green S				632	Water	
Kiton Green S Conc.						
Basic Green 3		SO_3H, OH	*hh, pp*	609	9:1	284, 286
Sevron Green B			*rr, vvv*		Methanol–Water	
Brilliant Blue F & R Extra		SO_3H				281
Brilliant Green Sulfonate		CN				288

Dye Name or Structure; CI Name and Number; Other Names	*Nominal Anion*[a,b]	*Notes Referring to Solvent*[b]	*Visible Spectrum* λ_{max} (nm)	*Visible Spectrum* *Solvent*
Hexakis(hydroxyethyl) Pararosaniline 	CN		600	Ethanol
New Green 	CN		615	Ethanol
Phenolphthalein 	CN	*xx*		
Malachite Green Ethiodide 	CN			

Hydroxyalkylated Pararosanilines	CN	*dd*		
Hydroxyalkylated New Fuchsins	CN	*dd*		
New Yellow	CN		463	Ethanol
Doebner's Violet	CN		575	Ethanol
New Red	CN		507	Ethanol

Dye Name or Structure; CI Name and Number; Other Names	*Nominal Anion*[a,b]	*Notes Referring to Solvent*[b]	*Visible Spectrum* λ_{max} (nm)	*Visible Spectrum* *Solvent*
Bis(hydroxyethyl) Doebner's Violet 	CN		597	Ethanol
"New Magenta" 	CN		547	Ethanol
Tetrakis(hydroxyethyl) Doebner's Violet 	CN		632	Ethanol
Trichloro Crystal Violet 	CN			

Slow Red	CN	503	Ethanol
	SO_3H		
	SO_3H		
	SO_3H		
	SO_3H		
	SO_3H	574	
	SO_3H		

Dye Name or Structure; CI Name and Number; Other Names	*Nominal Anion*[a,b]	*Notes Referring to Solvent*[b]	*Visible Spectrum* λ_{max} (nm)	*Visible Spectrum* *Solvent*
	SO_3H			
	SO_3H		630	
	SO_3H		620	
	SO_3H		618	
	SO_3H		600	



615



590

[a] Only the cyanide, bisulfite, and hydroxide ions are considered, regardless of the other anions present in the solution.
[b] More detailed descriptions of the compositions of photochromic materials tested are given in Macnair's review [255; tables 1A–4].
[c] Ethanol.
[d] Diethyl ether.
[e] 1,2-Dichloroethane.
[f] 1,1-Dichloroethane, cyclohexane–1,1-dichloroethane, or cyclohexane–1,2-dichloroethane mixtures.
[g] Benzene.
[h] Dimethylsulfoxide, neat and aqueous.
[i] Acetone.
[j] Acetic acid.
[k] Ethyl acetate.
[l] Ethyl bromide.
[m] 2-Methoxyethanol.
[n] Chloroform.
[o] Ethanol with KCN.
[p] Ethanol with KOH.
[q] Carboxylic acids—acetic to stearic; hydrocinnamic acid; ethyl and butyl acid phthalates.
[r] Octadecylnitrile, tributyl phosphate, aniline, 2-(*p-tert*-butylphenoxy)ethanol, tetraethyleneglycol dimethyl ether, or poly(ethylene glycols).
[s] Amides—formamide to stearamide; methylformamide or methylacetamide; dimethyl- or diethyl-formamide or acetamide.
[t] Three-to-one solutions of cellulose acetate with any of the following five-to-one plasticizer mixtures: Polyethylene Glycol 600[m]- butyl stearate, Polyethylene Glycol 600- butyl acetoxystearate, Dowanol EP[m]- butyl stearate, or Dowanol EP- butyl acetoxystearate.
[u] Water containing SO_2.
[v] Water containing bisulfite and papain.
[w] Poly(vinyl alcohol) with dimethylsulfoxide (5 : 1).

[x] Films, containing residual solvent, cast from the following solutions: ethanol–acetone solutions of vinyl acetate–vinyl alcohol copolymer; aqueous poly(vinyl alcohol); aqueous poly(vinyl pyrrolidone); or aqueous methyl vinylether–maleic acid copolymer.

[y] Methanol–dioxane with aqueous NH_4HSO_3.

[z] Paper impregnated with a toluene solution of poly(methyl methacrylate), stearic acid, and 2-(*p-tert*-butylphenoxy)ethanol, then dried.

[aa] Intramicellar impregnation of cellulose with the following swelling agents: *n*-propylamine, *n*-butylamine, *n*-hexylamine, 2-aminoethanol, dimethylformamide, acetic acid, dimethylsulfoxide, methylacetamide, dimethylacetamide, or formamide.

[bb] Films cast from an approximately 4 : 3 mixture of a 20% solution of cellulose acetate butyrate in toluene–ethyl acetate (1 : 1) and triallycyanurate in dioxane.

[cc] Films cast from a 2 : 1 mixture of a 25% solution of cellulose acetate butyrate in toluene–ethyl acetate (1 : 1) and the titanium esters of N,N,N′, N′-*tetrakis*(2-hydroxypropyl) ethylenediamine.

[dd] Pure water.

[ee] Films cast from aqueous gelatin or other hydrocolloids.

[ff] Dimethylsulfoxide with methanolic KCN.

[gg] 2-Methoxyethanol with methanolic KCN.

[hh] Water or aqueous methanol containing bisulfite.

[ii] Paper impregnated with *m*-dimethoxybenzene, acetonitrile, acetic acid, or phenyl methyl carbinol.

[jj] Ethanol–benzene.

[kk] Aqueous ethanol, methanol, aqueous methanol, aqueous acetone, benzene–methanol, carbon tetrachloride–methanol, cyclohexane–methanol, or chloroform–methanol.

[ll] Films cast from 3 : 1 solutions of cellulose acetate and either Polyethylene Glycol 600[19] or ethylene glycol phenyl ether as plasticizer.

[mm] Films, containing residual solvent, cast from solutions of either cellulose acetate in 2-methoxyethanol or poly(vinyl alcohol) in aqueous ethanol.

[nn] Films, containing residual solvent, cast from solutions of either cellulose acetate butyrate in 2-methoxyethanol or poly(vinyl acetate) in methanol.

[oo] Ethanol containing ammonia.

[pp] Aqueous methanol containing NH_4HSO_3 and urease.

[qq] Aqueous methanol containing NH_4HSO_3, with or without sodium dithionite.

[rr] Aqueous acid at pH 1.

[ss] Aqueous ammonia containing KCN.

[tt] Paper impregnated with aqueous solutions with or without hydrocolloids.

[uu] 2-Methoxyethanol containing HCl.

[vv] Aqueous methanol containing NH_4HSO_3, and glucose oxidase.

[ww] 9 : 1 Methanol–water.

[xx] Aqueous NaOH.



165 X = C=O
168 X = $(CH_2)_{1,2}$



174



172 R = Na
173 R = H



169

170 X = CN
171 X = OH



176



177 R = H
178 R = NH$_2$

179



175

Photochromic Polymethine Dyes

α, ω-bis(p-*Dimethylaminophenyl*)*polyenes*



Ar	*n*
C_6H_5	0, 1, 2
4-$(CH_3)_2NC_6H_4$	0, 1, 2
4-$(CH_3)_2CHC_6H_4$	0, 1, 2, 3, 4
4-$CH_3OC_6H_4$	0, 1, 2
4-$C_4H_9OC_6H_4$	0, 1, 2
3-$CH_3C_6H_4$	1, 2
4-*t*-$C_4H_9C_6H_4$	1, 2
4-$C_2H_5OC_6H_4$	1, 2
4-$C_5H_{11}C_6H_4$	1, 2
4-FC_6H_4	1
4-$F_3CC_6H_4$	1
2-$(C_6H_5)_2NC_6H_4$	1
3,4-$H_2N(OCH_3)C_6H_3$	1
2-Naphthyl	1, 2
4-ClC_6H_4	2
2,4-$Cl_2C_6H_3$	2
1-Naphthyl	2

α, α-bis(p-*dimethylaminophenyl*)*polyenes*



R	R
	
	
	
	
	
	
	

Miscellaneous polyenes















Basic Red 13



Basic Violet 7

Basic Red 14
Basic Red 15
Basic Violet 15



TABLE 11 (Cont'd)

Structure	λ_{max} (nm)
	930

555



400 & 630



TABLE III

PHOTOCHROMIC DYES

Molecular Structure	λ_{max} (nm)
	412, 330, 870

370-890



•These dyes were also useable as photosensitive but non-photochromic dyes in formulations which prevented the usual reversible color formation from taking place.

TABLE III (Cont'd)

Molecular Structure	λ_{max} (nm)
	550-675





TABLE III (Cont'd)

Molecular Structure	λ_{max} (nm)
	569

815



680



TABLE III (Cont'd)

Molecular Structure	λ_{max} (nm)
	630

620



380-400



TABLE V

PHOTOCHROMIC FORMULATIONS OF REPRESENTATIVE TRIPHENYLMETHANE DYES

Identification Number*	Structure	Solvent **	Additive	Effect of U.V.	Comments
PC 1011R (CI 42650)		**Methyl Cellosolve	KCN in MeOH	Slight photo-chromism	Light violet.
		DMSO	KCN in MeOH	Good photo-chromism	Light violet. Major absorption peak 595 mμ.
		Distilled Water	$NaHSO_3$	Good photo-chromism	Dark violet.
PC 1010 (CI 42555)		**Methyl Cellosolve	KCN in MeOH	Good photo-chromism	Violet.
		DMSO	KCN in MeOH	Good photo-chromism	Violet.
		Distilled Water	$NaHSO_3$	Good photo-chromism	Violet. Thermochromic

*The identification numbers are Polacoat numbers and Colour Index numbers. The structures of the dyes were obtained from the Colour Index, Volume 3.

**Methyl Cellosolve is a trade name for ethylene glycol monomethyl ether. DMSO refers to Dimethyl Sulfoxide.

TABLE V (Cont'd)

PHOTOCHROMIC FORMULATIONS OF REPRESENTATIVE TRIPHENYLMETHANE DYES

Identification Number	Structure	Solvent	Additive	Effect of U.V.	Comments
PC 10238 (CI 42510)		Methyl Cellosolve	KCN in MeOH	Fair photo-chromism	Light red.
		DMSO	KCN in MeOH	Good photo-chromism	Red. Major absorption peak 558 mμ.
		Distilled Water.	$NaHSO_3$	Good photo-chromism	Positive thermochromism
PC 10248 (CI 42520)		Methyl Cellosolve	KCN in MeOH	Good photo-chromism	Red.
		DMSO	KCN in MeOH	Good photo-chromism	Red. Major absorption peaks 290, 380 mμ.
		Distilled Water	$NaHSO_3$	Good photo-chromism	Red. Thermo-chromic

TABLE V (Cont'd)

PHOTOCHROMIC FORMULATIONS OF REPRESENTATIVE TRIPHENYLMETHANE DYES

Identification Number	Structure	Solvent	Additive	Effect of U.V.	Comments
PC 1090 (CI 42590)		Methyl Cellosolve	KCN in MeOH	Good photo-chromism	Violet. Major absorption peaks 633, 422 and 310 mμ.
		DMSO	KCN in MeOH	Good photo-chromism	Bright green. Major absorption peaks 625, 426 and 315 mμ.
		Distilled Water	$NaHSO_3$	Good photo-chromism	Can bleach either violet or colorless depending upon amount of bleach added. Thermochromic
PC 1091 (CI 42735)		Methyl Cellosolve	KCN in MeOH	Good photo-chromism	Red. Major absorption peaks 300 and 600 mμ.
		DMSO	KCN in MeOH	Good photo-chromism	Pink.
		Distilled Water	$NaHSO_3$	Good photo-chromism	Blue. Thermochromic

TABLE V (Cont'd)

PHOTOCHROMIC FORMULATIONS OF REPRESENTATIVE TRIPHENYLMETHANE DYES

Identification Number	Structure	Solvent	Additive	Effect of U.V.	Comments
PC 1092 (CI 42025)		Methyl Cellosolve	KCN in MeOH	Good photo-chromism	Green.
		DMSO	KCN in MeOH	Good photo-chromism	Green. Major absorption peaks 635, 420 and 308 mμ.
		Distilled Water	$NaHSO_3$	Good photo-chromism	Green.
PC 1093 (CI 42685)		Methyl Cellosolve	KCN in MeOH	Fair photo-chromism	Pink
		DMSO	KCN in MeOH	Good photo-chromism	Light red. Major absorption peaks 550 and 290 mμ.
		Distilled Water	$NaHSO_3$	Good photo-chromism	Red. Thermochromic

TABLE V (Cont'd)

PHOTOCHROMIC FORMULATIONS OF REPRESENTATIVE TRIPHENYLMETHANE DYES

Identification Number	Structure	Solvent	Additive	Effect of U.V.	Comments
PC 1094 (CI 42500)		Methyl Cellosolve	KCN in MeOH	Fair photo-chromism	Light red.
		DMSO	KCN in MeOH	Good photo-chromism	Light red. Major absorption peaks 550 and 294 mμ.
		Distilled Water	$NaHSO_3$	Good photo-chromism	Red.
PC 1095 (CI 42500)		Methyl Cellosolve	KCN in MeOH	Poor photo-chromism	Light orange.
		DMSO	KCN in MeOH	Poor photo-chromism	Light orange. Major absorption peak 560 mμ.
		Distilled Water	$NaHSO_3$	Good photo-chromism	Dye is very slightly soluble.

TABLE V (Cont'd)

PHOTOCHROMIC FORMULATIONS OF REPRESENTATIVE TRIPHENYLMETHANE DYES

Identification Number	Structure	Solvent	Additive	Effect of U.V.	Comments
PC 1104 (CI 42100)		Methyl Cellosolve	KCN in MeOH	Poor photo-chromism	Light green.
		DMSO	KCN in MeOH	Poor photo-chromism	Light green.
		Distilled Water	$NaHSO_3$	Good photo-chromism	Green.
PC 1106 (CI 42095)		Methyl Cellosolve	KCN in MeOH	No photo-chromism	
		DMSO	KCN in MeOH	No photo-chromism	
		Distilled Water	$NaHSO_3$	Good photo-chromism	Green.

TABLE V (Cont'd)

PHOTOCHROMIC FORMULATIONS OF REPRESENTATIVE TRIPHENYLMETHANE DYES

Identification Number	Structure	Solvent	Additive	Effect of U.V.	Comments
PC 1113 (CI 42085)		Methyl Cellosolve	KCN in MeOH	Fair photo-chromism	Light green.
		DMSO	KCN in MeOH	Good photo-chromism	Green. Major absorption peaks 635 and 430 mμ.
		Distilled Water	$NaHSO_3$	Good photo-chromism	Green.
PC 1113 (CI 42500)		Methyl Cellosolve	KCN in MeOH	Fair photo-chromism	Light red.
		DMSO	KCN in MeOH	Good photo-chromism	Red. Major absorption peaks 550 and 293 mμ.
		Distilled Water	$NaHSO_3$	Good photo-chromism	Red.

SALT-ISOMERISM TYPE PHOTOTROPIC DYES

Night Blue



Victoria Blue R



Brilliant Milling Blue B

Brilliant Blue F & R Ex.

Eriocyanine A



Methyl Blue



Aniline Blue



Eriochrome Cyanine R



Methyl Violet 6B



Iodine Green



Aniline Blue



Wool Violet 5 BN



Wool Violet 4 EM



Light Green SF
Yellowish



Iodine Violet



Methyl Violet



Crystal Violet



Ethyl Violet



Acid Green L Extra



Erioviridene B



Light Green SF



Victoria Green
(Malachite Green)



Red-Violet 5R



Brilliant Green "B"



Di-[4(N,N-diethylamine)phenyl]-[4-(N,N-diethyl-amine-2-methyl) phenyl] methyl carbonium



Tri-[4(N,N-dipropylamino)phenyl] methyl carbonium



Di-[4(N,N-diethylamino)phenyl]-[4(ethylamino)-phenyl] methyl carbonium



Di-[4(N,N-diethylamino)phenyl]-[4(N,N-diethylamino)naphthyl] methyl carbonium



Di-[4(N,N-dimethylamino)phenyl]-[4(hydroxy)phenyl] methyl carbonium



Tri-[4(N-propylamino)phenyl] methyl carbonium



Hectolene Blue DS-1398

Hectolene Blue DS-1823

Sevron Brilliant Red 4G

Di-[4(N,N-dimethylamino)phenyl]-[4(hydroxy)phenyl] methyl carbonium



Tri-[4(N-propylamino)phenyl] methyl carbonium



Hectolene Blue DS-1398

Hectolene Blue DS-1823

Sevron Brilliant Red 4G

Genacryl Red 6B

Genacryl Pink G

Sevron Brilliant - Red B

Sevron Brilliant - Red 3B

1,5-bis-[4(N,N-dimethylamino)phenyl]-1,5-bis-(phenyl)divinyl carbonium trifluoroacetate



1,1,3,3-tetrakis[4(N,N-dimethylamino)phenyl] vinyl carbonium perchlorate



1,5-bis-[4(N,N-dimehtylamino)phenyl]-1,5-bis-(phenyl) divinyl carbonium p-toluenesulfonate



1,7-bis-[4(N,N-dimethylamino)phenyl]-1,7-bis-(2,4-dichlorophenyl) trivinyl carbonium perchlorate



Di-[4(N,N-dimethylamino)phenyl vinyl]-[2,4-diphenyl-6-methane thiopyran] methyl carbonium perchlorate



1,7-bis-[4-(N,N-dimethylamino)phenyl]-1,7-bis-(4-chlorophenyl) trivinyl carbonium trifluoro-acetate



1,1,3-tris-[4-(N,N-dimethylamino)phenyl] divinyl carbonium perchlorate



1,1,7,7-tetrakis-[4-(N,N-dimethylamino)phenyl] trivinyl carbonium perchlorate



1,3-bis-[4-(N,N-dimethylamino)phenyl]-1,3-bis-(phenyl) vinyl carbonium perchlorate



1,1,5,5-tetrakis-[4-(N,N-diemthylamino)phenyl] divinyl carbonium perchlorate



1,5-bis-[4-(N,N-dimethylamino)phenyl]-1,5-bis-(phenyl) divinyl carbonium perchlorate



1,7-bis-[4-(N,N-dimethylamino)phenyl]-1,7-bis-(phenyl) trivinyl carbonium trifluoroacetate



1,1,5-tris-[4-(N,N-dimethylamino)phenyl] divinyl carbonium perchlorate



1(1,3,3-trimethyl indoline)-2-[4-(N,N-dimethyl-amino)phenyl] ethylene carbonium perchlorate



1(1,3,3-trimethyl indoline)-4-[4-(N,N-dimethyl-amino)phenyl] butylene carbonium perchlorate



1,1,3,3-tetrakis-[4(N,N-diethylamino)phenyl] vinyl carbonium perchlorate



1,1-bis-[4-(N,N-diethylamino)phenyl]-3,3-bis-[4-(N,N-dimethylamino)phenyl] vinyl carbonium perchlorate



1,1,5,5-tetrakis-[4-(N,N-diethylamino)phenyl] divinyl carbonium perchlorate



1,1-bis-[4-(N,N-dimethylamino)phenyl]-3-[4-(amino) phenyl]-3-methylvinyl carbonium perchlorate



Tris-[1,1-bis-[4(N,N-dimethylamino)phenyl] ethylene] methyl carbonium perchlorate



Tris-[1,1-bis-[4-(N,N-diethylamino)phenyl] ethylene] methyl carbonium perchlorate



1,1,5-tris-[4-(N,N-dimethylamino)phenyl] divinyl carbonium perchlorate



N[4-(N,N-dimethylamino) cinnamylidene] auramine



1,1-bis-[4-(N,N-dimethylamino)phenyl-3,4-bis-(phenyl)]-3,4-diazo butene carbonium



1,1,5,5-tetrakis-[4-(N,N-dimethylamino)phenyl]-2,3-diazo pentene carbonium



N-(N',N'-dimethylamino cinnamylidene)-N,N-diphenyl ammonium



Azo Polymethines

Dyes of the general structural type







Photochromic diazopolymethines



1,1,5,5-tetrakis-[4-(N,Np-dimethylamino)phenyl]-2,3-diazo pentene carbonium

Table 3. Representative Drug Molecules.

Name	Structure
Captopril	
Prostaglandin E_2	
2,3-dichloro-α-methylbenzylamine	
3'-deoxy-S-adenosyl-L-homocysteine	

Sinefungin



3,5-diiodo-4-hydroxybenzoic acid



6,6'-dithiobis (9-B-D-ribofuranosylpurine)



γ-aminobutyric acid



Gabaculine



N-(5'-phosphopyridoxyl)-4-aminobutyric acid



4-amino-hex-5-enoic acid



Baclofen



Adenosine



3-hydroxy-3-methylglutarate



Compactin



But-3-ynoyl-CoA



Suramin



L-3-iodotyrosine



L-3-iodo-α-methyltyrosine



Disodium cromoglycate



Adenosine 3',5'-cyclic monophosphate



D,L-B-(5-hydroxy-3-indolyl)-α-hydrazinopropionic acid



D,L-α-hydrazino-α-methyldopa



α-methyldopa



5-(3,4-dihydroxycinnamoyl)salicylic acid



N-(phosphonacetyl)-L-aspartate



P-glycolohydroxamate



5-(p-sulfamylphenylazo)salicylic acid



Coformycin



Formycin B



Thioinosinate



Phosphonoformate



Phosphonoacetate



Ridavirin



Sotalol



Cimetidine



Fuscaric acid



2-mercaptoethylamine



Mimosine



U-7130



Iproniazid



Trans-4-aminocrotonic acid



NSD 1055



Nicotinic acid



Kynurenic acid



Lentysine



Orotic acid



Polyoxin D



Cephalosporin



Penicillin



The electron transfer functionality, D, includes molecules which undergo a redox reaction which transfers electrons between the electron carriers and the A functionality where a redox reaction of A results in its activation to an excited energy state. The D functionality can be a natural electron carrier such as ubiquinone or a synthetic electron carrier such as methylene blue, phenazine methosulfate, or 2,6-dichlorophenolindophenol. Structures of electron transfer molecules appear below in Table 4.

Table 4. Representative Electron Transfer Molecules.

Name	Structure
Methylene Blue	
Ubiquinone	
2, 6 - dichlorophenolindophenol	

Phenazine methosulfate



Ferricyanide



A Representative Luminide

A representative luminide is the product of the covalent linkage of the polymethine dye with a bleaching drug such as Foscarnet and with a chemiluminescent reactive molecule such as luminol. This conjugate represents a molecule which releases Foscarnet in the presence of oxygen free radicals. The energy of the reaction of luminol with oxygen radicals undergoes intramolecular electronic energy transfer by radiative and nonradiative mechanisms. The latter dominate and include coulombic interactions, dipole-dipole resonance, and exchange interaction. These processes increase the quantum yield for drug release above that which would be produced by luminescence transfer alone. For example, Forster, in a quantum mechanical treatment of resonance transfer, in the region of spectral overlap involving allowed transitions of two well separated molecules has only considered dipole-dipole interactions in deriving an experimentally verified formula which predicts a distance of 5-10 nm as the distance at which transfer and spontaneous decay of the excited donor are equally probable. The formula predicts the transfer probability is inversely proportional to the separation distance raised to the sixth power. However, the donor and accepter functionalities of a Luminide are covalently linked; thus, since the separation distance is of the order of angstroms, the transfer probability is great. In fact, the efficiency of transfer has been studied in certain molecules which consist of two independent chromophores separated by one or more saturated bonds. In such cases, energy transfer over large

distances has been observed to be in agreement with predictions from Forster's Theory.

The Luminides can be prepared by known reactions where necessary, appropriate derivatives of the subunits are formed before coupling.

Representative examples of appropriate derivatization and coupling reactions are given in the following examples, illustrating the preparation of representative Luminides. These examples are not to be taken as an exhaustive listing, but only illustrative of the possibilities according to the present invention.

Representative Luminides with
Outline of Synthetic Pathway.

Luminides synthesis involves the chemical joining of three or four functionalities. A representative luminide of three functionalities comprises an energy donor molecule such as a chemiluminescent molecule, an energy acceptor molecule such as a photochromic molecule, and a drug. A representative luminide of four functionalities comprises the mentioned three functionalities and also an electron transfer functionality which can undergo an oxidation reduction reaction.

A three group Luminde can be formed by condensing a photochromic dye functionalized as an acid chloride with a chemiluminescent molecule possessing an alcoholic or amino group to form an ester or amide. The luminide pharmaceutical is then formed by addition of the drug bleaching agent. An exemplary pathway of this type appears in example 1.

Alternatively, the chemiluminescent or/and electron transfer functionality can be linked to the

energy acceptor functionality by formation of an ester or amide where the former functionality/functionalities is/are an acid halide as demonstrated in example 15.

Also, functionalities of the electron transfer and energy donor type can be linked to the energy acceptor part by an acylation reaction as demonstrated in examples 2, 3 and 8; by nucleophillic substitution as demonstrated in examples 4, 5, 6, 7, 9, 10, 12 and 17; by a carbanion mechanism as demonstrated in example 11; by a Grignard reaction as demonstrated in example 14, by a tosylate mechanism as demonstrated in example 13, or by a Wittig reaction as demonstrated in example 16. Similar reaction pathways can be used to link chemiluminescent molecules to energy donor molecules. The list of examples of reaction pathways is intended to be examplary and other pathways can be devised by one skilled in the art. Furthermore, only a representative number of luminides are shown and a vast number of other novel luminides can be made by one skilled in the art following the guidelines herein disclosed.

And, the disclosed exemplary luminides, and components: chemiluminescent molecules, photochromic molecules, energy transfer molecules, and drug molecules can be modified to further candidate components by addition of functional groups by one skilled in the art. Representitive groups include aklyl, cycloalkl, alkoxycarbonyl, cyano, carbamoyl, heterocyclic rings containing C, O, N, S, sulfo, sulfamoyl, alkoxysulfonyl, phosphono, hydroxyl, halogen, alkoxy, alkylthiol, acyloxy, aryl, alkenyl, aliphatic, acyl, carboxyl, amino, cyanoalkoxy, diazonium, carboxyalkylcarboxamido, alkenyl, thio,

cyanoalkoxycarbonyl, carbamoylalkoxycarbonyl, alkoxy carbonylamino, cyanoalkylamino, alkoxycarbonyl-alkylamino, sulfoaklylamino, alkylsulfamoylaklyl-amino, oxido, hydroxy alkyl, carboxy alkylcarbonyl-oxy, cyanoalkyl, carbonyloxy, carboxyalkylthio, arylamino, heteroarylamino, alkoxycarbonyl, alkyl-carbonyloxy, carboxyalkoxy, cyanoalkoxy, alkoxy-carbonylalkoxy, carbamoylalkoxy, carbamoylalkyl carbonyloxy, sulfoalkoxy, nitro, alkoxyaryl, halogenaryl, amino aryl, alkylaminoaryl, tolyl, alkenylaryl, allylaryl, alkenyloxyaryl, allyloxyaryl, allyloxyaryl, cyanoaryl, carbamoylaryl, carboxyaryl, alkoxycarbonylaryl, alkylcarbonyoxyaryl, sulfoaryl, alkoxysulfoaryl, sulfamoylaryl, and nitroaryl.

EXPERIMENTAL SECTION I

Synthesis

Synthesis of MTL 7-3, and MTL J-1

Step A: Preparation of p-N,N-dimethylaminobenzoyl chloride



In a round bottom flask fitted with a reflux condenser is placed 4 g of p-dimethylaminobenzoic acid and 8 ml of oxalylchloride. The evolution of gas starts immediately and the spontaneous reaction is run at room temperature for 15 minutes. 8 ml of toluene is added and and the mixture is heated to gentle reflux for one hour. The reaction mixture is then distilled to dryness under reduced pressure to produce a blue-green solid which is washed with ether and dried on a watch glass.

Step B: Preparation of p-dimethylaminobenzanilide



A solution of 0.95 g of aniline in 10 ml of dry ether containing 2.2 g of K_2CO_3 was heated to reflux temperature. To the refluxing mixture 2 g of p-dimethylaminobenzoyl chloride was added as a powder slowly through the condenser port. The reaction was refluxed for 1.5 hours and the ether distilled off. Cold water was added to the residue and the p-dimethylaminobenzanilide collected by filtration. Yield 1.51 g orange-red powder. Anilide functionality confirmed by IR.

Step C: Preparation of
p-N,N dimethyl-p-N-ethyl-N-2-chloroethylbenzophenone.



1.5 g of dry, powdered p-dimethylbenzanilide, 2.4 g of N-ethyl-N-2-chloroethylaniline, and 1.3 ml of phosphorus oxychloride were mixed in a 25 ml 2-necked flask, fitted with a thermometer immersed in the reation mixture and a reflux condenser having a $CaCl_2$ drying tube on top. The reaction was warmed slowly until an exothermic reaction occured. The temperature was maintained at less than 100°C by periodic immersion of the flask in ice water. The reaction was then maintained at 95°C for one hour to yield a dark green liquid. The reaction mixture was then hydrolyzed in a 150 ml beaker with the addition of a solution of 1.36 ml of concentrated HCl to 10.4 ml of distilled H_2O. The beaker was covered with a watch glass and heated on a hot water bath for 1.5 hours to yield a green-yellow solution. 10:1 cold water was added to the hydrolyzed mixture to form a brilliant purple solution which was filtered. The filtered product was dissolved in a minimum volume of ethanol, and twice the volume of cold H_2O was added. The ketone was then extracted in an equal volume of chloroform which was removed by distillation to dryness under reduced pressure. Brilliant purple solid product. Ketone confirmed by IR and NMR.

Step D: Preparation of 1-(4-N,N-dimethylaminophenyl)-1-(4-N-ethyl-N-2-chloroethylphenyl) ethylene.



One ml of a 3 molar etherial solution of magnesium bromide was evaporated almost to dryness under reduced pressure in a 50 ml three necked flask equipped with a thermometer and nitrogen sparger. The grey moist solution was suspended in 1.3 ml of dry benzene. The flask was then equipped for refluxing by the addition of a condenser fitted with a $CaCl_2$ drying tube and an addition funnel. 0.017 moles of the ketone dissolved in 4.4 ml of boiling benzene was then placed in an addition funnel and added dropwise to the warmed methyl magnesium bromide-benzene slurry over a half hour period. The resulting solution was refluxed for one hour. The completion of the reaction was evident by the color change of the solution from brilliant purple to blue. The reaction mixture was cooled to room temperature, and 0.785 ml of saturated NH_4Cl was cautiously added. Additional NH_4Cl was added until two layers were apparent with the blue alcohol product in the bottom H_2O layer. 1.7×10^{-3} g of p-toluenesulphonic acid was added, and the solution was boiled on a water bath with the addition of benzene until the evaporation of H_2O was complete and only the benzene layer remained. The acid contained in the reaction mixture was then removed by the addition of 0.73×10^{-3} g of sodium bicarbonate. The solvent was reduced to dryness under reduced pressure to yield light blue crystals.

Step E: Preparation of a perchlorate of 1,5-di-(p-N-2-chloroethyl-N-ethylaminophenyl)-1,5-bis-(p-N,N-dimethylaniline)-1,3-pentadiene.







A mixture of 8.7×10^{-4} moles of 1-(4-N,N-dimethylaminophenyl)-1-(4-N-2-chloroethyl-N-ethylaminophe-nyl)ethylene, 0.13 ml of ethyl orthoformate, and 0.39 ml of acetic anhydride was treated with a solution of 0.035 ml of 72 percent perchloric acid and 0.35 ml of acetic acid previouly cooled to $0^{\circ}C$. The resulting mixture was allowed to stand at room temperature for 8 days, after which time it was treated with 0.22 ml of ether and kept an additional day at room temperature. The condensation product was washed with acetic acid, ethanol, and ether. The pale blue-green crystals were dissolved in a minimum volume of warm dry ethanol. The solution was centrifuged to pellet a white precipitate. The dark blue supernatant solution was removed and distilled to dryness under reduced pressure. The blue crystals where placed on watch glass and placed in the dark. The structure of the condensation compound was confirmed by IR and NMR.

Step F: Preparation of 1,5-di-(p-N-2-(N-(4-aminobutyl)-N-ethyl isolminol)-N-ethylaminophenyl)-1,5-bis-(p-N,N-dimethyla niline)-1,3-pentadiene.



+ ClO_4^-







Pyridinium perchlorate

5 mg (1.8×10^{-5} moles) of N-(4-aminobutyl)-N-ethylisoluminol was suspended in 0.1 ml of pyridine in a small test tube. 30 mg (3.6×10^{-5} moles) of the pentadiene was dissolved in 0.5 ml of pyridine and 0.25 ml of DMSO. This latter solution was added dropwise to the former while vigorously stirring at room temperature initially then with intermittant imersion in a water bath at 35°C. The isoluminol which was only slightly soluble in pyridine went into solution as the reaction progressed. The reaction mixture was stirred and intermittantly immersed in the water bath at 35°C until the reaction was complete. This reaction and all subsequent reactions were protected from direct light.

Step G: Preparation of Luminide, MTL 7-3 (2,6-di-(p-N-2-(N-(4-aminobutyl)-N-ethylisoluminol)-N-ethylamino-phenyl)-2,6-bis-(p-N,N-dimethylanilino)-3,5-hexadinenitrile).







(38)



(37)

Compound 31 is acylated with an active oxalate such as 32 to yield adduct 33. Adduct 33 is treated with Ridavirin to yield the final product 34.

Example 9.

The compound shown as formula 38 is prepared as follows:





(34)



(33)

Compound 27 is reacted with adduct 28 which is formed by akylation of an active oxalate by a methylene blue derivative.

The product adduct 29 is treated with adenosine 3', 5'-cyclic monophosphate to yield the final product 30.

Example 8.

The compound shown as formula 34 is prepared as follows:



(31)



(32)





Example 7.

The compound shown as formula 30 is prepared as follows:



Compound 23 is prepared with the appropriately substituted ethoxy groups which is then reacted with a phthalhydrazide such as 24 to form adduct 25. The final product 26 is formed by treatment of adduct 25 with γ-aminobutyric acid.


H2NCH2CH2CH2COOH
(26)
N(CH3)2
OCH2CH3
O
OCH2CH2CH2NH2
CH=CHCH=
(CH3)2N
CH2CH2O
HN(CH2)4N
CH3
CH2
NH
O

(25)



Compound 19 which is formed using an appropriately substituted aniline is reacted with adduct 20 to give adduct 21 where adduct 20 is formed by alkylation of the aromatic ring of an active oxalate derivative with a molecule which can accept electrons via electron transport. Adduct 21 is treated with Baclofen to form the product 22.

Example 6.

The compound shown as formula 26 is prepared as follows:



(23)

+



(24) →



(21) + (22)

Compound 15 is reacted with the carboxylate 16 to form the ester 17 where 16 is formed by linking an oxidation reduction agent such as a derivative of 2, 6-dichloro phenolindophenol with a dioxene carboxylate derivative. The ester 17 is reacted with p-glycolohydroxamate to give the final product.

Example 5.

The compound shown as formula 22 is prepared as follows:



(19)

(20)





(17) + (18)

Compound 11 is acylated with a biacridinium derivative such as 12 to give adduct 13 which is treated with 5-(p-sulfamylphenylazo) salicylic acid to give the final product 14.

Example 4.

The compound shown as product 18 is prepared as follows:



(15)



(16)



(14)



(13)



Example 3.

The compound shown as formula 14 is prepared as follows:



(11)

+



(12)

$AlCl_3$

→

Compound 7 is acylated with an acridinium ester such as compound 8 to give adduct 9 which is treated with prostaglandin E_2 to give the final product 10.



(10)



(9)

Example 2.

The compound shown as formula 10 is prepared as follows:



Phenolphthalein is converted to the corresponding acid chloride by treatment with oxalyl chloride. The acid chloride is reacted with chloromethylamine to form the corresponding amide which is in turn reacted with a dioxetan such as compound 4 to give adduct 5 where compound 4 is prepared from the appropriate starting dioxtene by a method described by Schaap. The adduct 5 is converted to the final product by treatment with Captopril.





(6)


X⁻
HO
C
CNHCH2Cl
O
OH
(3)
+
O
O
H
O—O
N
CH3N
CH2
NH2
S
N(CH3)2
X⁻
(4)
X⁻
HO
C
CNHCH2
O
OH
CH2NH
(5)
O
O
H
O—O
N
N
CH3
S
N(CH3)2

Further Exemplary Material

Example 1.

The compound shown as formula 6 is prepared as follows:



MTL J-1 was prepared by the equimolar addition of disodium phosphonoformate dissolved in H_2O to a DMSO solution of 1,5-di-(p-N-2-(N-(4-aminobutyl)-N-ethylisoluminol) -N-ethylaminophenyl)-1,5-bis(p-N,N-dimethylaniline)-1,3 -pentadiene
such that the final solvent was 4:3 DMSO/H_2O. The reaction mixture was protected from light, and the colorless reaction product solution was packaged in light protecting vials and refrigerated at 4°C.

Methods of synthesis of triphenylmethane dyes appear in Appendix I.

Methods of synthesis of polymethine dyes appear in Appendix II.

Methods of synthesis of azo and diazopolymethine dyes appear in Appendix III and IV, respectively.

Methods of synthesis of quaternary ammonium salt poly methines appear in Appendix V.

Methods of synthesis of the intermediates, tetramethylortho carbonate and substituted ethylenes appear in Appendix VI.

Methods of synthesis of indoline based dyes appear in Appendix VII.

Methods of synthesis of dyes with more than one chromophore appear in Appendix VIII.

Methods of forming a leucocyanide appear in Appendix IX.



Step H: Preparation of Luminide MTL J-1

(5-phosphonoformate-1,5-di-(p-N-2-(N-(4-aminobutyl)-N-ethylisoluminol)-N-ethylaminophenyl)-1,5-bis-(p-N,N-dimethylaniline)-1,3-pentadiene).



5 mg of solid KCN and 1 ml of distilled H_2O were added to the blue-grey solution of 1,5-di-(p-N-2-(N-(4-aminobutyl)-N-ethylisoluminol)-N-ethylaminophe-nyl)-1,5-bis-(p-N,N-dimethylanilino)-1,3-pentadiene in pyridine/DMSO solvent. The solution was acidified by addition of sulphuric acid and the evolving HCN gas was removed by evaporating the solvent to dryness under reduced pressure. The pale green crystals were redissolved in DMSO to yield a pale green liquid. IR and NMR confirmed the structure.

Compound 35 is reacted with an alkyl halide derivatived active oxalate such as 36 to give adduct 37 which is treated with phosphonoacetate to give the final product 38.

Example 10.

The compound shown as formula 42 is prepared as follows:



(39)

+



(40)



(41)



(42)

Compound 39 is prepared using the proper chloromethyl substituted benzene and reacted with a dioxene derivative such as 40 to yield adduct 41. Adduct 41 is treated with U-7130 to give the final product 42.

Example 11.

The compound shown as formula 47 is prepared as follows:





(45)



(46)



(47)

Compound 43 is dehydrated and treated with an indole ketone derivative dioxene such as 44 to give intermediate adduct 45 which is hydrolyzed to the ketone adduct 46. Adduct 46 is treated with N-(phosphonacetyl)-L-asparate to yield the final product 47.

Example 12.

The compound shown as formula 51 is prepared as follows:



(48)



(49)



(50)


H2NCH2CH=CHCOOH
TRANS
(CH3)2N
(CH3)2N
+C-CH=
N
N(CH3)2
CH2NH(CH2)4N
CH3
CH2
NH
NH
O
O
H2NCH2CH=CHCO
O
TRANS

(51)

Compound 48 is prepared from the proper chloromethyl naphthalene and reacted with a phthalhydrazide such as 49 to give adduct 50 which is reacted with trans-4-aminocrotonic acid to give the final product 51.

Example 13.

The compound shown as formula 56 is prepared as follows:



(52)





(53)



(54)



(55)



(56)

Compound 52 is reacted with p-toluene sulfonyl chloride to give tosylate adduct 52 which is reacted with an active oxamide that has an alcoholic function such as 54 to give ether adduct 55. The adduct 55 is reacted with compactin to give the final product 56.

Example 14.

The compound shown as formula 62 is prepared as follows:



(57)



(58)



(59)



(60)



(61)



(62)

Compound 57 is reacted with Mg to form the Grignard reagent 58 which is reacted with a dioxene indole derivative with an aldehyde or ketone functionality such as 59 to give the alcohol 60. Adduct 60 is reacted with 4-amino-hex-5-enoic acid, 61, to give the final product 62.

Example 15.

The compound shown as formula 67 is prepared as follows:



(63)



(64)



(65)



(66)



(67)

The compound 63 is reacted with an acid halide such as 64 to give adduct 65. The acid halide 64 is prepared from the corresponding acid by reaction with oxalyl chloride. The original acid is prepared by reacting a phenazine possessing an alkyl halide and a carboxylic acid function with an indole derivative that has a amino group. The adduct amide 65 is reacted with but-3-ynoyl-CoA, 66, to give the final product 67.

Example 16.

The compound shown as formula 71 is prepared as follows:



(68)



(69)



(70)



(71)

The aldehyde compound 68 is reacted with a phosphonium ylid of a ubiquinone nucleus linked to a indole dioxene derivative such as 69 to form adduct ethylene 70. (The ylid 69 is formed by an acylation reaction of an indole derivative dioxene with a ubiquinone adduct followed by reaction with triphenylphosphine.) The adduct 70 is reacted with DL-2-hydrazino-α-methyldopa to form the final product 71.

Example 17.

The compound shown as formula 76 is prepared as follows:



(72)



(73)



(74)



(75)



(76)

The alkylchloride 72 is reacted with alkyl amine Lophine derivate 73 to yeild adduct 74 which is reacted with disodium cromoglycate, 75, to form the final product 76.

Preparations and Routes of Administration of Luminides

Luminides can be administered orally, intramuscularly or intraveneously.

Medicinal formulations which contain one or more Luminide compounds as the active compound can be prepared by mixing the Luminide (s) with one or more pharmacologically acceptable excipients or diluents, such as, for example, fillers, emulsifiers, lubricants, flavor correcting agents, dyestuffs or buffer substances, and converting the mixture into a suitable galenic formulation form, such as, for example, tablets, dragees, capsules or a solution or suspension suitable for parenteral administration. Examples of excipients or diluents which may be mentioned are tragacanth, lactose, talc, agar - agar, polyglycols, ethanol and water. Suspensions or solution in water can preferably be used for parenteral administration.

Also, Luminides can be prepared as sterile lyophilized powder to which a sterile solvent such as water or dimethylsulfoxide is added. Luminides are also prepared as a sterile lyophilized powder containing deoxycholate to effect a colloidal dispersion of insoluble Luminide. These preparations are administered as injectables including intramuscular and intravenous administration.

Topical Luminides can be prepared as a cream, lotion, gel, and ointment.

It is also possible to administer the active compounds as such without excipients or diluents, in a suitable form, for example in capsules.

Luminides can be packaged employing the usual sorts of precautious which the pharmacist generally observes. For example, the preparations may be packaged in light protecting vials and may be refrigerated if necessary.

EXEMPLARY LUMINIDE PHARMACEUTICALS

Prostaglandins possess potent renal, cardiac, hemodynamic, and other physiological effects; however, the free agents are 95% inactivated during one passage through the pulmonary circulation and are essentially eliminated in 90 seconds from intravascular injection. A luminide which is resistant to intravascular inactivation comprising a C functionality of prostaglandin A_1 A_2, B_1, E_1, E_2, or an analogue which possesses a vasodilatory effect on coronary arteries and other human vascular beds is an agent for the treatment of ischemic heart disease and is a antihypertensive agent with a long halflife. A luminide which is resistant to intravascular inactivation comprising a C functionality of postaglandin E, F, A or an analogue which possesses a positive cardiac inotropic effect is an inotropic agent with a long halflife. A luminide which is resistant to intravascular inactivation comprising a C functionality of prostaglandin A, E, or an analogue prostaglandin which possesses natriuretic and diuretic activity is a diuretic agent with a long halflife. A luminide which is resistant to intravascular inactivation comprising a C functionality of prostaglandin A, G, E_1, E_2 or an analogue such as 15(S)-15-methyl PGE_2 methylester, 16,16-dimethyl PGE_2, AY-22,093, AY-22,469, AY-22,443, or 15(R)-15-methyl PGE_2 which inhibits

gastric acid secretion is an agent for the treatment of peptic and duodenal ulcer disease with a long halflife. A luminide which is resistant to intravascular inactivation comprising a C functionality of prostaglandin D_2, E_1 or an analogue which inhibits platelet aggregation is an antithromboembolic agent with a long halflife. A luminide which is resistant to intravascular inactivation comprising a C functionality of prostaglandin E_1, E_2 or an analogue which causes bronchial dilatation is an agent for the treatment of asthma and allergic and hypersentivity reactions with a long halflife. A luminide which is resistant to intravascular inactivation comprising a C functionality of prostaglandin F_2 or an analogue which causes abortion by luteolysis is an agent for therapeutic abortion with a long halflife. A luminide which is resistant to intravascular inactivation comprising a C functionality of prostaglandin A_2, E_1, E_2, or an analogue which induces erythropoiesis by stimulating the release of erythropoietin from the renal cortex is an agent for the treatment of anemia. A luminide which is resistant to intravascular inactivation comprising a C functionality of prostaglandin E or an analogue which modulates T lymphocytes to decrease their ability to reject an allogenic graft is an agent to prolong allograft survival.

A cellular permeant luminide comprising a C functionality of cellular impermeant 2' -isopropyl -4' -(trimethylammonium chloride) -5' -methylphenyl piperidine -1-carboxylate (Amo 1618) which inhibits the cyclization of trans-geranyl-geranyl-PP to copalyl-PP during Kaurene synthesis is a fungicidal agent.

A cellular permeant luminide comprising a C functionality of cellular impermeant adenosine cyclic 3', 5'-monophosphate or an analogue which inhibits the release and formation of phlogistic mediators such as histamine and kinins is an agent for treating asthma and hypersensitivity and anaphylactic reactions.

A cellular permeant luminide comprising a C functionality of cellular impermeant 4'-sulfamylphenyl - 2-azo -7-acetamido -1-hydroxynaphthalene -3,6-disulfonate (Neoprontosil), 4'-sulfamyl -2, 4-diaminoazobenzene (Prontosil), or 5-(p-sulfamylphenylazo) salicylic acid (Lutazol) which possess potent carbonic acid anhydrase inhibition is a diuretic agent.

A cellular permeant luminide comprising a C functionality of a cellular impermeant analogue of S-adenosyl homocysteine or sinefungin is an oncostatic agent.

A cellular permeant luminide comprising a C functionality of the cellular impermeant phosphoglycolohydroxamate which inhibits Class II aldolases present in bacterial and fungi and is noninhibitory of Class I aldolases present in animals is an antibacterial and antifungal agent.

A cellular permeant luminide comprising a C functionality of a cellular impermeant inosine analogue such as formycin B which inhibits nucleotide phosphorylase during nucleotide metabolism is an agent for disorders of purine metabolism such as gout, is an agent that alters the toxicity and/or antitumor behavior of other analogue - containing nucleosides such as 6-thioguanosine or 6-mercaptopurine ribonueleoside, and is an immunosuppressive agent by disruption of purine metabolism.

A cellular permeant luminide comprising a C functionality of cellular impermeant phosphonoformate (Foscarnet) which inhibits the HIV reverse transcriptase enzyme is an agent for the treatment of acquired immunodeficiency syndrome. The synthesis and the results of treatment of C3H mice infected with Raucher Spleen Focus Forming Virus with MTL J-1, a cellular permeant luminide comprising a C functionality of phosphonoformate, is given in Experimental Secions 1 and 3, respectively.

A cellular and blood-brain barrier permeant luminide comprising a C functionality of cellular and blood brain-barrier impermeant γ-amino-butyric acid (GABA) which is the major inhibitory neurotransmitter in the mannalian central nervous system or comprising a C functionality of a cellular and blood-brain barrier impermeant inhibitor of the GABA-degrading enzyme, GABA: 2-oxoglutarate aminotransferase such as gabaculine, N-(5'-phosphopyridoxyl) -4-aminobutyric acid, ethanolamine -o-sulfate, γ-vinyl GABA, or γ-acetylenic GABA; or comprising a C functionality of a cellular and blood-brain barrier impermeant compound which enhances GABA release such as Baclofen is an anti-convulsant, muscle relaxant, sedative, and anxiolytic agent.

A cellular permeant luminide comprising a C functionality of a cellular impermeant oligonucleotide which binds to RNA or DNA and blocks transcription or translation of HIV or P-glycoprotein gene products is an agent for the treatment of AIDs and chemotherapeutic drug, resistance, respectively.

A blood-brain barrier permeant luminide comprising a C functionality of blood-brain barrier impermeant adenosine which binds to brain purinergic

receptors to suppress opiate withdrawal is an agent for the management of opiate withdrawal syndrome.

A slowly releasing peripherally acting luminide comprising a C functionality of adenosine which causes coronary vasodilatation is a long acting agent for the treatment of ischemic heart disease.

A cellular permeant luminide comprising a C functionality of cellular impermeant 3-hydroxy -3-methylglutarate, 3-hydroxybutyrate, 3-hydroxy -3-methylpentanoate, 4-bromocrotonyl -CoA, but-3-ynoyl -CoA, pent -3-ynoyl -CoA, dec -3-ynoyl-CoA, ML-236A, ML-236B (compactin), ML-236C, mevinolin, mevinolinic acid, or a mevalonic acid analogue which is an inhibitor of 3-hydroxy -3-methylglutaryl -CoA reductase which catalyzes the rate-limiting and irreversible step of cholesterol synthesis where inhibition at this step does not lead to the accumulation of nonmetabolizable precursors is an anticholesterol agent.

A cellular permeant luminide comprising a C functionality of cellular impermeant thioinosinate which suppresses T lymphocytes is an immunosuppressant agent.

A cellular permeant luminde comprising a C functionality of cellular impermeant Suramin, which is a powerful inhibitor of energy driven calcium uptake by the sarcoplasmic reticulum and is an intracellular inhibitor of Na^+-K^+ ATPase where both activities increase intracellular calcium concentrations with a concomitant inotropic effect is a cardiac inotropic agent.

A cellular permeant luminide comprising a C functionality of a cellular impermeant norepinephrine N-methyltransferase inhibitor such as 2,3-dichloro -α-methylbenzylamine, 2,3-dichlorobenzylamine,

2,3-dichlorobenzamidine, or 3,4-dichlorophenylacetamidine is a specific epinephrine action blocking agent.

A cellular permeant luminide comprising a C functionality of cellular impermeant adenosine cyclic 3',5'-monophosphate or a cAMP analogue which blocks the synthesis of fatty acids and cholesterol in the liver is an antilipidemic agent.

A cellular permeant luminide comprising a C functionality of a cellular impermeant inhibitor of dihydroxyphenylalanine decarboxylase during the synthesis of epinephrine and norepinephrine such as psitectorigenin, genistein, 3',4',5,7-tetrahydroxy-8-methylisoflavone, orbol, 8-hydroxygenistein, 3',5,7-trihydroxy-4',6-dimethylisoflavone, 3',5,7-trihydroxy-4',8-dimethoxyisoflavone, D,L-B-(5-hydroxy-3-indolyl)-α-hydrazinopropionic acid, D,L-α-hydrazino-α-methyldopa, D,L-B-(3-indolyl) -α-hydrazinopropionic acid, a derivative of phenylalanine such as N-methyl-3,4-dopa, α-acetamido-3,4-dimethyoxycinnamic acid, DL-α-methyl-3,4-dopa, α-methyl-B-(3-hydroxy-4- methoxyphenyl)alanine, α-methyl-3,4-dimethoxyphenylalanine, or d-catechin; D,L-B-(3-indolyl)-α-methyl-α- hydrazinopropionic acid (R)-3[3,4-dihydroxyphenyl]-1- fluoropropylamine, (S)-α-fluoromethyldopa, (S)-α-fluoromethyltyrosine, 5-(3,4-dihydroxycinnamoyl) salicylic acid, 3-hydroxycinnamic acid, caffeic acid, 3-mercaptocinnamic acid, α-methyl-3-hydroxycinnamic acid, α-ethyl-3- hydroxycinnamic acid, 3-hydroxy-w-nitrostyrene, 3,4-dihydroxyhydrocinnamic acid, 3-hydroxybenzalacetone, 3-hydroxychalone, 3-hydroxybenzal furanyl ketone, 3-hydroxybenzal thiophenyl ketone, 3',4'-dihydroxyflavone, 8-0-glucoseflavone, flavone, 3-hydroxyphenyl pyruvic acid, 3,4-dihydroxy-

phenylpyruvic acid phenylthiopyruvic acid, 4-hydroxy-phenylpyruvic acid, dithiosalicyclic acid, 1-hydroxy2-naphthoic acid, 3-hydroxy-7-sulfo-2-naphtholic acid, 3,5-dihydroxy-2-naphtholic acid, 4-chlorocinnamic acid, 2-chlorocinnamic acid, 2,4-dichlorocinnamic acid, 3-nitrocinnamic acid, 3,5-dibromo-2-hydroxycinnamic acid, 2,4,6-triiodo -3-hydroxycinnamic acid, 2-hydroxy-4'-cyanochalone, 4-(4-hydroxycinnamoyl) benzylnitrile, 2-(4-hydroxycinnamoyl) -1,4-dihydroxybenzene, quercetin-6'-sulfonic acid, 5-(2-hydroxy-3,5-dibromocinnamoyl) salicylic acid or 5-(3-hydroxycinnamoyl) salicylic acid is an antihypertensive agent.

A sperm permeant luminide comprising a C functionality of sperm impermeant inhibitors of acrosin, a proteolytic enzyme located in the acrosome of sperm, such as tosyl lysine chloromethyl ketone, N-α-tosyl-L-arginine chloromethyl ketone, or ethyl p-guanidinobenzoate is a contraceptive agent.

A cellular permeant luminide comprising a C functionality of cellular impermeant adenosine cyclic 3',5'-monophosphate (cAMP), N^6,O^2-dibutyryladenosine cyclic 3',5'-monophosphate or an analogue which produces an inotropic response is a cardiac inotropic agent.

A cellular permeant luminide comprising a C functionality of a cellular impermeant adenosine kinase enzyme inhibitor such as 6,6'-dithiobis (9-B-D-ribofuranosylpurine) is a chemotherapeutic agent and an immunosuppressive agent.

A mitochondrial and blood-brain barrier permeant luminide comprising a C functionality of a mitochondrial and blood-brain barrier impermeant inhibitor of monoamine oxidase such as phenylhydrazine, phenylethylidenehydrazine, isopropylhydrazine, or iproniazid is an antidepressant.

A cellular and blood-brain barrier permeant luminide comprising a C functionality of a cellular and blood-brain barrier impermeant inhibitor of catechol-o-methyltrasferase such as 3,5-diiodo-4-hydroxybenzoic acid, S-3'-deoxyadenosylL-homocysteine, pyrogallol, R04-4602, gallic acid, 3,5-dihydroxy-4-methylbenzoic acid, 1,3-dihydroxy-2-methoxybenzene, 1-hydroxy-2,3-dimethoxybenzene, 2-hydroxy-1,3-dimethoxybenzene, 1,3-dihydroxy-4-methoxybenzene, catechol, 3,4-dihydroxybenzoic acid, caffeic acid, 5,6-dihydroxyindole, noradnamine, dopacetamide, H 22/54, quercetin, nordihydroguaiaretic acid, U-0521, arterenone, methylspinazarin, MK 486, dopa, papaveroline, isoprenaline, 7,8-dihydroxy-chlorpromazine, 3-hydroxy-4-pyridone, tetrahydroi-soquinoline pyridoxal 5'-phosphate, iodoacetic acid, 3-mercaptotyramine, dehydrodicaffeic acid dilactone, methylspinazorin, 3',5,7-trihydroxy-4',6-dimeth-oxyisoflavone, 3',5,7-trihydroxy- 4',8-dimeth-oxyisoflavone, 6,7-dihydromethylspinazarin, S-adenosylhomocysteine, S-tubercidinylhomocysteine, 3',8-dihydroxy-4',6,7-trimethoxyisoflavone,7-0-methylspi nochrome B, 6-(3-hydroxybutyl)-7-0-methylspinachrome B, 3,5-diiodosalicyclic acid, or pyridoxal-5'-phosphate is an antidepressant agent which increases brain levels of monoamines and is an agent to block the metabolism of L-dopa administered for the treatment of Parkinsonism.

A cellular permeant luminide comprising a C functionality of a cellular impermeant inhibitor of adenosine deaminase which blocks the metabolism of adenosine such as coformycin, arabinosyl-6-thiopurine, 6-methylthioinosine, 6-thioinosine, 6-thioguanosine, N^1-methyladenosine, N^6-methyladenosine, 2-fluorodeoxyadenosine, 2-fluoroadenosine, inosine,

2'-deoxyinosine, deoxycoformycin, 1,6-dihydro-6-hydroxymethyl purine ribonucleoside, erythro-9-(2-hydroxy-3-nonyl)adenine, or 9-B-D-arabinofuranosyl-6-hydroxylaminopurine is a vasodilatory agent, an immunosuppressive agent, a chemotherapeutic potentiating agent, and an agent to enhance cardiac recovery following ischemia. The mechanism in the first case involves the accumulation of adenosine which is a vasodilatory agent; the mechanism in the second case involves disruption of purine metabolism; the mechanism in the third case involves the disruption of the degradation of purine analogue chemotherapeutic agents; the mechanism in the fourth case involves blocking the loss of catabolic products of adenosine triphosphate in the form of purine nucleotides and oxypurines during ischemia. Additional luminides effective in enhancing post ischemic cardiac recovery by the latter mechanism include those with C moietics of inhibitors of adenylate kinase, 5'-nucleotidase, and adenosine translocase such as p^1,p^5-diadenosine pentaphosphate, α,B-methylene adenosine diphosphate, and nitrobenzyl-6-thioinosine, respectively.

A blood-brain barrier permeant luminide comprising a C functionality of a blood-brain barrier impermeant inhibitor of γ-aminobutyric acid uptake such as D,L-2,4-diaminobutyric acid, D,L-B-hydroxy GABA, (-)-nipecotic acid, trans-4-aminocrotonic acid, cis-3-aminocyclopentane- 1-carboxylic acid, trans-3-aminocyclopentane-1-carboxylic acid, B-guanidinopropionic acid, homohypotaurine, 4-aminopentanoic acid, homotaurine, B-alanine, imidazoleacetic acid, 6-aminohexanoic acid, D,L-carnitine, D,L-2,6-diaminopimelic acid, D,L-2-fluoro GABA, guanidino acetic acid, 2-hydrazinopropionic acid, taurine, D,L-orni-

thine, or sulphanilamine potentiates the inhibitory action of GABA and is a muscle relaxant, anticonvulsant, sedative, and anxiolytic agent.

A cellular permeant luminide comprising a C functionality of cellular impermeant inositol 1,4,5-triphosphate which is a major second messenger for stimulating a whole range of cellular processes such as contraction, secretion, and metabolism is an agent for activating these processes including secretion of neural transmitters to function as an agent for the treatment of mental disorders or secretion of insulin to function as a hypoglycemic agent.

A cellular permeant luminide comprising a C functionality of cellular impermeant guanosine 5' cyclic monophosphate or 8-bromo guanosine 5' cyclic monophosphate which relaxes smooth muscle is an antihypertensive and bronchodilator agent.

A cellular and blood-brain barrier permeant luminide comprising a C functionality of a cellular and blood-brain barrier impermeant inhibitor of the uptake system for glycine, the inhibitory synaptic transmitter of the spinal cord, such as hydrazinoacetic acid is an agent for spinal reflex inhibition.

A cellular permeant luminide comprising a C functionality of a cellular impermeant isoquinolinesulfonamide inhibitor of protein kinase C, cAMP-dependant protein kinase, or cGMP-dependent protein kinase such as N-(2-aminoethyl)- 5-isoquinolinesulfonamide is an agent which blocks the secretion, contraction, and metabolic events regulated by these mediators of external physiologic stimuli.

A cellular permeant luminide comprising a C functionality of cellular impermeant Ribavirin which

is active against HSV-1 and 2, hepatitis, and influenza viruses, or phosphonoacetic acid which is a highly specific inhibitor of Herpes Simplex virus induced polymerase and is active against HSV-1 and HSV-2, or adenine arabinoside (ara-A), cytosine arabinoside (Ara-C), ara-A 5'-monophosphate (ara-AMP), or hypoxanthine arabinoside (ara-Hx) which is active against HSV or phagicin which is active against vaccinia and HSV, or 4-fluoroimidazole, 4-fluoroimidazole-5-carboxylic acid, 4-fluoroimidazole- 5-carboxamide, 5-fluoro-1-B-D-ribofurano- sylimidazole-4-carboxamide, 5-amino-1-B-D-ribofuranosyl- imidazole-4-carboxamide, poly (I) • poly (C), sinefungin, iododeoxyuridine, 9-(2-hydroxy-ethoxymethyl) guanine, gliotoxin, distamycin A, netropsin, congocidine, cordycepin, 1-B-D-arabinofuranosylthymine, 5,6-dihydroxy-5-azathymidine, pyrazofurin, toyocamycin, or tunicamycin is an antiviral agent.

A cellular permeant luminde which comprises a C functionality of a cellular impermeant inhibitor of fungal chitin synthetase such as polyoxin D, nikkomycin Z, or nikkomycin X; or which comprises a C functionality of an impermeant antifungal agent such as ezomycin A_1, A_2, B_1, B_2, C_1, C_2, D_1, or D_2 or platenocidin, septacidin, sinefungin, A9145A, A9145C, or thraustomycin is an antifungal agent.

A blood-brain barrier permeant luminide comprising a c functionality of a blood-brain barrier impermeant inhibitor of central nervous system carbonic anhydrase such as methazolamide, or 2-benzoylimino-3-methyl-Δ^4-1,3,4-thiadiazoline-5-sulfonamide substituted at the benzolyl group with 3,4,5-trimethoxy, 2,4,6-trimethoxy, 2,4,5-trimethoxy,

4-chloro, 4-bromo, 4-iodo, or hydrogen is an anticonvulsant agent.

A cellular and blood-brain barrier permeant luminide comprising a C functionality of a cellular and blood-brain barrier impermeant inhibitor of dopamine-B-hydroxylase during the synthesis of norepinephrine and epinephrine such as fuscaric acid, 5-(3',4'-dibromobutyl)picolinic acid, 5-(3'-bromobutyl) picolinic acid, 5-(3',4'-dichlorobutylpicolinic acid, YP-279, benxyloxyamine, p-hydroxybenzyloxyamine, U-21,179, U-7231, U-6324, U-0228, U-5227, U-10,631, U-10,157, U-1238, U-19,963, U-19,461, U-6628, U-20,757, U-19,440, U-15,957, U-7130, U-14,624, U-22,996, U-15,030, U-19,571, U-18,305, U-17,086, U-7726, dimethyldithiocarbamate, diethyldithiocarbamate, ethyldithiocarbamate, 2-mercaptoethylguanidine, thiophenol, 2-mercaptoethylamine, 3-mercaptopropylguanidine, 3-mercap- topropyl-N-methylguanidine, 2-mercaptoethanol, 2-mercaptoethyl-N-methylguanidine, 2-mercaptoethyl-N,N'- dimethylguanidine, 4,4,6-trimethyl -3,4-dihydropyrimidine-2-thiol, N-phenyl-N'-3-(4H-1,2,4-trizolyl)thiourea, methylspinazarin, 6,7-dimethylspinazarin, 7-0-methyspinochrome B, 6-(3-hydroxybutyl)-7-0-methylspinachrome B, aquayamycin, chrothiomycin, frenoclicin, N-n-butyl-N'-3-(4H-1,2,4-trazolyl) thiourea, propylthiouracil, mimosine, mimosinamine, or mimosinic acid is an antihypertensive agent.

A cellular permeant luminide of a cellular impermeant inhibitor of histidine decarboxylation during the synthesis of histamine such as 2-hydroxy-5-carbomethoxybenzyloxyamine, 4-toluenesulfonic acid hydrazide, 3-hydroxy benzyloxyamine, hydroxylamine, aminooxyacetic acid, 4-bromo-3-hydroxybenzyloxyamine (NSD-1055), rhodanine substituted in

the 3 position with p-chlorophenethyl, p-chlorobenzyl, p-methylthiobenzyl, p-methylbenzyl, p-fluorobenzyl, amino, 3,4-dichlorobenzyl, p-bromobenzyl, p-methoxybenzyl, p-bromoanilino, p-iodoanilino, p-chloroanilino, p-toluidino, anilino, 2,5-dichloroanilino, dimethylamino, or p-methoxyphenyl; 2-mercaptobenzimidazole-1,3-dimethylol, 4-bromo-3-hydroxy -benzoic acid, 4-bromo-3-hydroxybenzyl alcohol, 4-bromo-3-hydroxy-hippuric acid, (R,S)-α-fluoromethyl- histidine, (S)-α-fluoromethylester, L-histidine ethyl ester, L-histidinamide, D,L-3-amino-4-(4-imidazolyl)-2-butanone, 2-bromo-3-hydroxybenzyloxyamine, 5-bromo-3- hydroxybenzyloxyamine, 4,6-dibromo- 3-hydroxybenzyloxyamine, aminooxypropionic acid, benzyloxyamine, 4-bromo-3-benzenesulfonyloxybenzyloxyamine, 3',5,7-trihydroxy-4',6- dimethoxyisoflavone, lecanoric acid, N-(2,4-dihydroxybenzoyl)- 4-aminosalicylic acid, or 3',5,7-trihydroxy-4',8- dimethoxyisoflavone is an agent for the treatment of allergy, hypersensitivity, gastic ulcer, and inflamation.

Luminides also comprise C functionalities of pharmaceutical molecules as appear in Physicians Desk Reference, Edward R. Barnhart, 41th ed., 1987, Medical Economics Company Inc., N.J.; USAN and the Dictionary of Drug Names, ed. by Mary C. Griffiths, The United States Pharmacopedial Convention, (1986); and The Pharmacological Basis of Therapeutics, ed. by A.G. Gilman, L. Goodman, A. Gilman, 7th ed., (1985), MacMillan Publishing Co., N.Y., N.Y., (incorporated by reference) where the pharmacokinetics and/or the pharmacodynamics of these agents are altered via delivery to the site of action by way of a luminide agent such that the therapeutic effect or therapeutic

ratio is enhanced. Some examples follow which are not meant to be exhaustive.

A luminide with high permeance to the blood-brain barrier comprising a C functionality of a centrally acting converting enzyme inhibitor such as captopril which possesses a lesser blood-barrier permeance is an agent with increased efficacy of the central nervous system antihypertensive effect of the centrally acting converting enzyme inhibition including captopril.

A luminide with an A moiety which reacts with free radicals and electron carriers in the cytosol of bacteria to effect release of the C moiety and which possesses greater permeance or B-lactamase resistance than its C moiety of a bacterial wall synthesis inhibitor such as a penicillin, cephalosporin, or cephamycin is a more efficacious and broad spectrum antibacterial agent than the free C moiety.

A luminide possessing more favorable pharmacokinetics or pharmacodynamics than its C moiety of an agent which blocks bacterial synthesis of tetrahydrofolate such as a sulfonamide (an analogue of p-aminobenzoic acid) including sulfanilamide, sulfadiazine, sulfamethoxazole, sulfisoxazole, or sulfacetamide or an inhibitor of dihydrofolate reductace including pyrimethamine, cycloguanil, trimethoprin, isoaminopterin, 9-oxofolic acid, or isofolic acid is a more efficacious antibacterial than the free C moiety.

A luminide possessing more favorable pharmacokinetics or pharmacodynamics than it C functionality of a bactericidal agent such as nalidixic acid or oxolinic acid is a more efficacious antibacterial than the free C moiety.

A luminide possessing more favorable pharmacokinetics or pharmacodynamics than its C moiety of an

inhibitor of bacterial protein synthesis such as vancomycin, an aminogylcoside, erythromycin, tetracyclin, or chloramphenicol is a more efficacious antibacterial agent than the free C moiety.

A luminide prossessing more favorable pharmacokinetics or pharmacodynamics than its C moiety of an inhibitor of viral DNA polymerase such as vidarabine is a more efficacious antiviral agent than the free C moiety.

A luminide possessing more favorable pharmacokinetics or pharmacodynamics than its C moiety which is tuberculostatic or tuberculocidal such as isoniazid or aminosalicyclic acid is a more efficacious agent for the treatment of tuberculosis than the free C moiety.

A luminide possessing more favorable pharmacokinetics or pharmodynamics than its C moiety of an anthelmintic agent such as oxamniquine, piperazine, metronidazole, diethylcarbamazine, paromomycin, niclosamide, bithionol, metrifonate, hycanthone, dichlorophen, or niclosamide is a more efficacious anthelmintic agent than the free C moiety.

A luminide possessing more favorable pharmacokinetics or pharmacodynamics than its C moiety of an H_2-blocking agent such as cimetidine or ranitidine is a more efficacious anti-ulser agent than the free C moiety.

A luminide possessing more favorable pharmacokinetics or pharmacodynamics than its C moiety of an agent which blocks release of norepinephrine such as sotalol, guanethidine, pindolol, pronethalol, KO 592, practolol, oxprenolol, or pronethalol is an antiarrhythmic, antihypertensive and antipsychotic agent.

A luminide possessing more favorable pharmacokinetics or pharmacodynamics than its C moiety of a xanthine oxidase inhibitor such as allopurinol, thioinosinate, 5,7-dihydroxypyrazolo [1,5-a] pyrimidine substituted at the 3 position with hydrogen, nitro, bromo, chloro, phenyl, 3-pyridyl, p-bromophenyl, p-chlorophenyl, p-acetylanilino, p-tolulyl, m-tolulyl, naphthyl, or 3,4-methylenedioxyphenyl; 8-(m-bromoacetamidobenzylthio)hypoxanthine, 8-(m-bromoacetamidobenzylthio)hypoxanthine, guanine substituted at the 9 position with phenyl, 4-chlorophenyl, 3-chlorophenyl, 3,4-dichlorophenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 4-dimethylaminophenyl, 4-aminophenyl, 3-aminophenyl, 3-trifluormethylphenyl, 4-benzamido, 4-carboxylphenyl, 4-methylpheyl, 4-ethylphenyl, 3-methylphenyl, B-naphthyl, or 4-ethoxyphenyl; 4,6-dihydroxypyrazolo [3,4-d] pyrimidine, 4-trifluoromethylimidazoles substituted at the 2 position with phenyl, p-chlorophenyl, p-methoxyphenyl, p-acetylanilino, p-nitrophenyl, p-dimethylaminophenyl, p-cyanophenyl, p-fluorophenyl, p-carboxyphenyl, m-chlorophenyl, 3,4-dichlorophenyl, 4-pyridyl, 3-pyridyl, 2-quinolyl, 6-quinolyl, 4-quinolyl, 7-quinolyl, 2-pyrazinyl, or 1-(2-pyridyl-4-trifluoromethyl-5-bromoimidazolyl; 5-(4-pyridyl)-1,2,4-triazoles substituted at the 5 position with 4-pyridyl, 3-pyridyl, 2-pyridyl, phenyl, p-chlorophenyl, m-chlorophenyl, p-sulfonamidophenyl, 3,5-dichlorophenyl, 3,5-dicarboxyphenyl, 6-quinolyl, 2-furyl, 4-pyridazinyl, 2-thienyl, 2-pyrimidinyl, 4-pyrimidinyl, or 4-pyrazinyl; difunisal, 4(or 5)-(2-aminoethylthio-azo)imidazole-5(or 4)-carboxamide, 4 (or 5)-diazoimidazole-5(or 4)-carboxamide , or S-[5(or 4)-carbamoyl-4(or 5)-imidazolyl azo] cysteine is a

more efficacious agent for the treatment of gout and hyperuricemic conditions than the free C moiety.

A luminide possessing more favorable pharmacokinetics or pharmacodynamics than its C moiety which inhibits DNA synthesis such as a bis-thiosemicarbazone, 3,5-diisopropylsalicyl- hydroxamic acid, 4-hydroxybenzoylhydroxamic acid, 3-methylsalicyl-hydroxamic acid 2,5-dihydroxybenzoylhydroxamic acid, or 2-hydroxy-3,4,5-trimethoxybenzoylhydroxamic acid; or which inhibits nucleotide synthesis such as N-(phosphoacetyl)-L-aspartate which inhibits asparatate transcarbamylase during pyrimidine synthesis, or azaserine or 6-diazo-5-oxo-L-norleucine which inhibits purine synthesis at the phosphoribosyl-formyl-glycineamidine synthetase step; or which is an antifolate such as methotrexate, 2,4-diamino-5-benxyl-6-(4-phenylbutyl) pyrimidine, 2,4-diamino- 5-phenyl-6-(4-phenylbutyl) pyrimidine, 2,4-diamino-5-phenyl- 6-(3-anilinopropyl) pyrimidine, 2-amino-4-hydroxy-5-phenyl- 6-(3-p-aminobenzoyl-glutamic acid propyl) pyrimidine, N-[p-[[(2,4-diamino-6-quinazolinyl)methyl]methylamino] benzoyl]-L-glutamic acid, N-[p-[2,4-diamino-5-methylquinazolinyl)methylamino]benzoyl] -L-aspartic acid, N-[p-[[(2-amino-4-hydroxy-6-quinazolinyl) methyl]methylamino] benzoyl]-L-glutamic acid, 2,4-diaminoquinazolines: CCNSC 105952, CCNSC 112846, CCNSC 121346, CCNSC 122761, CCNSC 122870, CCNSC 529859, CCNSC 529860, or CCNSC 529861; 8-aza GMP, 7-deaza-8-aza GMP, 2'-dGMP, B-D-arabinosyl GMP, pentopyranine A-G, B-ribofuranosyl-1,3-oxazine-2,4-dione, pyrazofurin, 6-(p-chloroacetylanilinomethyl)-5-(p-chlorophenyl)-2,4- diaminiopyridine, 6-(p-chloracetylvinylanilinomethyl)-5- (p-chlorophenyl)-2,4-diaminopyridine, 6-(p-chloroacetyl- ethylanilino-

methyl)-5-(p-chlorophenyl)-2,4-diamino pyridine, 6-(p-chlorophenylbutylanilinomethyl)-5-(p-chlorophenyl)-2,4- diamino pyridine, p-(2,6-diamino-1,2-dihydro-2, 2-dimethyl- S-triazin-1-yl) phenylpropionyl sulfanilylfluoride or variants of the propionamide bridge of acrylamido, N-ethylsulfonamido, N-ethylcaboxamido, oxyacetamido, or oxythyloxy; or which inhibits purine or pyrimidine synthesis such as xylosyladenine, 6-azauridine, 5-aminouridine, 5-azaorotic acid; or which inhibits nucleotide interconversion such as hadacidin, 6-mercaptopurine, azathioprine, nitro-dUMP,psicofuranine, decoyinine, 5-fluorouracil, 5-fluorodeoxyuridine, shadowmycin; or which inhibits nucleotide utilization such as cytosine arabinoside, arabinosyladenine; or which becomes incorporated into polynucleotides such as 8-azaguanine, tubercidine, toyocamycin, sangivamycin, formycin, 7-deazainosine, 8-azainosine, or 7-thia-7, 9-dideazainosine; or which is a glyoxalase inhibitor such as Glyo-I, or Glyo-II, is a more efficacious antineoplastic agent than the free C moiety.

A luminide possessing more favorable pharmacokinetics or pharmacodynamics than its C moiety of an agent which blocks synthesis of prostaglandin A_2 which effects platelett aggregation such as salicylic acid, pyrogallol, 5,8,11,14-eicosatetraynoic acid, α-naphthol, guaiacol, propylgallate, nordihydroguiaretic acid, N-0164, benzydamine, 9,11-azoprosta-5, 13-dienoic acid, 2-isopropyl-3-nicotinylindole, is a more efficacious antithrombotic agent than the free C moiety.

A luminide possessing more favorable pharmacokinetics or pharmacodynamics than its C moiety of an agent which blocks prostaglandin synthetase such as indomethacin, sulindac, tolmetin, mefenamic acid,

ibuprofen, naproxen, fenoprofen, fluribiprofen, ketoprofen, meclofenamic acid, flufenamic acid, niflumic acid, benzydamine, oxyphenbutazone, asprin, acetaminophen, salicylamide, 0-carboxydiphenylamine, tolectin, diclofenac, 2,7-dihydroxynaphthalene, 5-(4-chlorobenzoyl)- 1-methylpyrrole-2-acetic acid, 5-(4-methylbenzoyl)-1,4- dimethylpyrrole-2-acetic acid, 5-(4-chlorobenzoyl)-1,4- dimethylpyrrole-2-acetic acid, 5-(4-fluorobenzoyl)-1,4- dimethylpyrrole-2-acetic acid, 5-(4-chlorobenzoyl)-1,4-dimethylpyrrole-2-(2-propionic acid), 5,6-dehydro-arachidonate, 11,12-dehydroarachidonate, or 5,8,11,14-eicosatetraynoate; or of an agent which blocks lipoxygenase or blocks leukotriene action such as BW755C, FPL 55712, or U-60,257 is a more efficacious nonsteroidal anti-inflammatory agent than the free C moiety.

A luminide possessing more favorable pharmaco-kinetics or pharmacodynamics than its C moiety of an antiarrhythmic agent such as procainamide or quinidine is a more efficacious antiarrhythmic agent than the free C moiety.

A luminide possessing more favorable pharmaco-kinetics or pharmacodynamics than its C moiety of an inhibitor of hepatic synthesis of Vitamin K dependent clotting factors such as warfarin sodium, dicumarol, 4-hydroxycoumarin, phenprocoumon, or acenocoumarol is a more efficacious anticoagulant than the free C moiety.

A luminide possessing more favorable pharmaco-kinetics or pharmacodynamics than its C moiety which directly relaxes vascular smooth muscle such as hydralazine, minoxidil, or isoxsuprine is a more efficacious antihypertensive agent than the free C moiety.